Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216248 · ClinicalTrials.gov registry record · Phase 2
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
A Phase 2 study of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT07216248 is a Phase 2 study of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) that is actively recruiting participants, run by University of Utah. The registered enrollment target is 160 participants, above the 51-participant average among 5 other Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials with a reported enrollment target (214% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07216248, a Phase 2 study of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
Conditions Studied
Interventions
- DRUG relugolix + ARPI
- DRUG Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI
- DRUG relugolix or androgen deprivation therapy (ADT) + ARPI
- DRUG relugolix + ARPI.
Study Locations (1)
Utah
- Huntsman Cancer Institute at University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2031-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216248
The ClinicalTrials.gov registry entry for NCT07216248 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 51-participant average among 5 other Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials with a reported enrollment target (214% higher). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) appearing as the primary indexed condition, and to 4 interventions - of which relugolix + ARPI is the first listed.
NCT07216248 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT07216248 about?
NCT07216248 is a clinical study titled "Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer". The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
What is the current status of trial NCT07216248?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-10-27. Estimated completion is 2031-10.
What conditions does trial NCT07216248 study?
This clinical trial studies the following conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
What interventions are being tested in trial NCT07216248?
The interventions under investigation include: relugolix + ARPI (DRUG), Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI (DRUG), relugolix or androgen deprivation therapy (ADT) + ARPI (DRUG), relugolix + ARPI. (DRUG).
Who is sponsoring clinical trial NCT07216248?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216248 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
COMPLETED · Phase 2
-
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
RECRUITING · Phase 1
-
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
RECRUITING · Phase 1
-
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
ACTIVE NOT RECRUITING · Early Phase 1
-
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.